AIN457 150 mg + AIN457 300 mg + Placebo
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Moderate to Severe Chronic Plaque-Type Psoriasis
Conditions
Moderate to Severe Chronic Plaque-Type Psoriasis
Trial Timeline
Sep 16, 2012 → May 4, 2017
NCT ID
NCT01640951About AIN457 150 mg + AIN457 300 mg + Placebo
AIN457 150 mg + AIN457 300 mg + Placebo is a phase 3 stage product being developed by Novartis for Moderate to Severe Chronic Plaque-Type Psoriasis. The current trial status is completed. This product is registered under clinical trial identifier NCT01640951. Target conditions include Moderate to Severe Chronic Plaque-Type Psoriasis.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01640951 | Phase 3 | Completed |
Competing Products
20 competing products in Moderate to Severe Chronic Plaque-Type Psoriasis